|
Cardium Announces Appointment of Paul A. Foster, M.D. To Lead Generx and Excellarate Late-Stage Development Activities
|
 |
July 28, 2008, San Diego --
Cardium Therapeutics (Amex: CXM) announced the appointment of Paul
A. Foster, M.D. as
Chief Medical Officer to lead the Company's late-stage clinical
development activities at Cardium's Tissue Repair Company for the
MATRIX Phase 2b clinical study that is evaluating its Excellarate
product candidate for the treatment of diabetic ulcers, and the
AWARE Phase 3 clinical study that is evaluating its Generx product
candidate as a potential treatment for recurrent myocardial ischemia.
Dr. Foster, who is currently Cardium's Vice President and Medical
Officer, will assume study oversight responsibilities for both
Cardium's and the Tissue Repair Company's clinical programs.
Dr.
Robert Engler, the Company's Chief Medical Advisor who has
been involved in the Generx trials since their inception, will
continue
to play an active role in those studies, and Dr. Randall Moreadith
will continue to focus on evaluating potential new business
development and medical device opportunities for the Company.
 |
|
"We are very pleased to
have Paul head up development of our key product candidates
as they move through late-stage clinical trials," stated
Christopher J. Reinhard, Chief Executive Officer and Chairman
of Cardium Therapeutics.
"Paul's leadership and extensive
clinical experience will greatly assist us as we advance
our Generx candidate now in Phase 3, and Tissue Repair's
Excellarate candidate, which is expected to complete its
key Phase 2 study this year." |
Dr. Foster was previously Chief Medical Officer and Vice President of Clinical
Development and Regulatory Affairs at Reata Pharmaceuticals. He has held leadership
clinical development and medical affairs positions at IDEC Pharmaceuticals Corporation,
Biogen Idec and Alpha Therapeutic and also has experience in the medical device
arena, previously holding director positions at Abbot Laboratories and Dade Behring.
He is Board Certified in Internal Medicine and Hematology. He received his B.S.
degree in Chemistry from the University of Michigan, and his M.D. degree and
medical training at Duke University.
About Cardium
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies,
Inc. and the Tissue Repair Company, are medical technology companies
primarily focused
on the development, manufacture and sale of innovative therapeutic products and
devices for cardiovascular, ischemic and related indications. Cardium's lead
product candidate, Generx™ (alferminogene tadenovec, Ad5FGF4), is a DNA-based
growth factor therapeutic being developed for potential use by interventional
cardiologists as a one-time treatment to promote and stimulate the growth of
collateral circulation in the hearts of patients with ischemic conditions such
as recurrent angina. For more information about Cardium and its businesses, products
and therapeutic candidates, please visit http://www.cardiumthx.com or
view its 2007
Annual
Report.
Cardium's InnerCool Therapies subsidiary
is a San Diego-based medical technology company in the emerging
field of patient temperature modulation therapy to rapidly
and controllably cool the body in order to reduce cell death and damage following
acute ischemic events such as cardiac arrest or stroke, and to potentially lessen
or prevent associated injuries such as adverse neurological outcomes. For more
information about Cardium's InnerCool subsidiary and patient temperature modulation,
including InnerCool's Celsius Control System™ and the CoolBlue™ System,
please visit http://www.innercool.com.
Cardium's Tissue Repair Company subsidiary
(TRC) is a San Diego-based biopharmaceutical company focused on
the development of growth factor therapeutics for the treatment
of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate™,
is a DNA-activated collagen gel for topical treatment formulated with an adenovector
delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB).
Excellarate is initially being developed to be administered once or twice for
the potential treatment of non-healing diabetic foot ulcers. Other potential
applications for TRC's Gene Activated Matrix™ (GAM™) technology include
therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease)
and orthopedic products, including hard tissue (bone) and soft tissue (ligament,
tendon, cartilage) repair. For more information about Cardium's Tissue Repair
Company subsidiary, please visit http://www.t-r-co.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed
in this press release are forward looking and reflect numerous
assumptions and involve a variety
of risks and uncertainties, many of which are beyond our control and may cause
actual results to differ materially from stated expectations. For example, there
can be no assurance that critical personnel can be retained, that human clinical
trials can be conducted and completed in an efficient and successful manner,
that product modifications or launches will be successful or that the resulting
products will be favorably received in the marketplace, that results or trends
observed in one clinical study will be reproduced in subsequent studies, that
our products or product candidates will prove to be sufficiently safe and effective,
that necessary regulatory approvals will be obtained or that our products or
product candidates will not be unfavorably compared to competitive products that
may be regarded as safer, more effective, easier to use or less expensive. Actual
results may also differ substantially from those described in or contemplated
by this press release due to risks and uncertainties that exist in our operations
and business environment, including, without limitation, risks and uncertainties
that are inherent in the development of complex biologics and therapeutic hypothermia
devices and in the conduct of human clinical trials, including the timing, costs
and outcomes of such trials, our ability to obtain necessary funding, regulatory
approvals and expected qualifications, our dependence upon proprietary technology,
our history of operating losses and accumulated deficits, our reliance on collaborative
relationships and critical personnel, and current and future competition, as
well as other risks described from time to time in filings we make with the Securities
and Exchange Commission. We undertake no obligation to release publicly the results
of any revisions to these forward-looking statements to reflect events or circumstances
arising after the date hereof.
Cardium Therapeutics™ and Generx™ are
trademarks of Cardium Therapeutics, Inc.
Tissue Repair™, Gene Activated Matrix™, GAM™ and Excellarate™ are
trademarks of the Tissue Repair Company.
InnerCool Therapies®, InnerCool®, Celsius Control System™, Accutrol™, CoolBlue™ and RapidBlue™ are
trademarks of InnerCool Therapies, Inc.
Source: Cardium
Therapeutics, Inc. |
